The Patent Finder

Chrysalis Pharma AG

Also on record
Records under this name other than patents Chrysalis Pharma AG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 10 of 10 · Back to Chrysalis Pharma AG

PatentTitleStatus Expires Confidence
US 8,383,678Type a gelatin capsule containing PUFA in free acid form
Formerly held
Lapsed on the fee record
Ended Feb 26, 2025 · From the USPTO record
Lapsed on the fee recordEnded Feb 26, 2025From the USPTO record
US 9,132,112Type A gelatin capsule containing PUFA in free acid form
Lapsed on the fee record
Ended Sep 15, 2023 · From the USPTO record
Lapsed on the fee recordEnded Sep 15, 2023From the USPTO record
US 7,960,370Type A gelatin capsule containing PUFA in free acid form
Formerly held
Lapsed on the fee record
Ended Jun 14, 2023 · From the USPTO record
Lapsed on the fee recordEnded Jun 14, 2023From the USPTO record
US 10,314,789Soft gelatin encapsulated pharmaceutical composition of cis-5,8,11,14,17-eicosapentaenoic acid in free acid form and cis-7,10,13,16,19-docosapentaenoic acid in free acid form
Lapsed on the fee record
Ended Jun 11, 2023 · From the USPTO record
Lapsed on the fee recordEnded Jun 11, 2023From the USPTO record
US 9,050,308DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Formerly held
Lapsed on the fee record
Ended Jun 9, 2023 · From the USPTO record
Lapsed on the fee recordEnded Jun 9, 2023From the USPTO record
US 9,050,309DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Lapsed on the fee record
Ended Jun 9, 2023 · From the USPTO record
Lapsed on the fee recordEnded Jun 9, 2023From the USPTO record
US 9,012,501Type A gelatin capsule containing PUFA in free acid form
Lapsed on the fee record
Ended Apr 21, 2023 · From the USPTO record
Lapsed on the fee recordEnded Apr 21, 2023From the USPTO record
US 10,117,844DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Lapsed on the fee record
Ended Nov 6, 2022 · From the USPTO record
Lapsed on the fee recordEnded Nov 6, 2022From the USPTO record
US 5,792,795Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
Term ended
Term ended no later than Aug 11, 2018 · Low confidence
Term endedTerm ended no later than Aug 11, 2018Low confidence
US 5,948,818Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
Formerly held
Term ended
Term ended no later than Sep 7, 2019 · Low confidence
Term endedTerm ended no later than Sep 7, 2019Low confidence
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited